This phase 1b trial studies the biologic effect of 9cUAB30 on early stage breast cancer.
9cUAB30 is a retinoid X receptor (RXR)-selective retinoid that acts in a tissue selective
manner with the goal of minimizing side effects, a necessary feature of agents under
development for cancer prevention.
Early-Stage Breast Carcinoma, Invasive Breast Carcinoma